Windward Bio Group AG plans to raise over $100 million through a U.S. IPO to support the development of its clinical-stage asthma drug, WIN378, which has shown promising Phase 2/3 results. The company expects pivotal trial data by mid-2027 and targets the growing severe asthma market. While backed by experienced management and institutional investors, Windward faces risks related to clinical trials, regulatory approval, and funding. If valued reasonably, the IPO is likely to attract strong institutional interest.
Windward Bio Group's IPO plans provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 02:12 WIB: out of 150 priced US health stocks, 12 rose and 138 fell. Notable movers include ALMS at USD 5.79 (-11.60%), INO at USD 1.44 (-11.11%) with 54% sell orders, and RXRX at USD 3.46 (-10.95%) with 75% buy orders.
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Following Binance's $6.3 billion hack, the Federal Reserve and the Office of the Comptroller of the Currency (OCC) have contacted U.S. banks to inquire about any unusual activity, service disruptions, or system vulnerabilities. This oversight aims to...
Fastly's stock fell 41% over the past month, including a 27% drop after its Q3 2026 earnings report, despite beating earnings estimates and raising revenue guidance. The company posted record revenue growth and positive free cash flow, driven by risi...
